Laboratory device for “Circulating Tumor Cells” (CTCs) isolation Client: PARITHERA
Treatment resistance is killing cancer patients. It should not. Some cancer cells develop mechanisms to adapt and become resistant. As these cells become predominant patients stop responding to treatment. Today's invasive sampling methods hinder regular monitoring. Parithera ExTrace enables accurate treatment decision guidance & monitoring from one simple blood draw. An alternative to tissue biopsy is to study cells which detach from the solid tumors and find access to the blood stream. The so-called circulating tumor cells (CTCs) are retrieved via Liquid Biopsy.Parithera ExTrace enables clinicians to monitor treatment response and choose the best therapy based on single cell sequencing data. Parithera’s innovative approach is based on two inventions in the domain of CTC isolation and sequencing preparation.